This article is for informational and educational purposes only. Retatrutide is an investigational drug that is NOT approved by the FDA or any regulatory agency. Nothing here constitutes medical advice. Consult a licensed healthcare provider before making any decisions about your health.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three incretin and metabolic hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple agonist mechanism distinguishes it from currently approved therapies like semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual agonist), and has generated significant interest due to its remarkable weight loss data in early clinical trials.
The addition of glucagon receptor activation is the key differentiator. While GLP-1 and GIP work primarily through appetite suppression and insulin signaling, glucagon contributes direct metabolic effects that earlier drugs in this class do not provide.
The Triple Agonist Mechanism
Each of retatrutide's three receptor targets contributes distinct physiological effects:
- GLP-1 receptor: Reduces appetite by acting on hypothalamic hunger centers, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the mechanism shared with semaglutide (Ozempic/Wegovy).
- GIP receptor: Works synergistically with GLP-1 to improve insulin sensitivity and may enhance fat tissue metabolism. GIP agonism is thought to amplify weight loss beyond what GLP-1 alone achieves, as demonstrated by tirzepatide (Mounjaro/Zepbound).
- Glucagon receptor: This is the novel component. Glucagon activation increases hepatic energy expenditure (thermogenesis), promotes fatty acid oxidation in the liver, and directly reduces hepatic fat accumulation. In essence, glucagon makes the body burn more energy — even at rest — rather than relying solely on reduced caloric intake.
The combination creates a dual approach to weight loss: reduced energy intake (GLP-1/GIP) plus increased energy expenditure (glucagon). This thermogenic component is a meaningful addition because most GLP-1-based therapies produce weight loss primarily through appetite suppression, which can plateau over time.
Phase 2 Clinical Data
The landmark Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Participants were randomized to placebo or one of four retatrutide dose levels (1mg, 4mg, 8mg, or 12mg) administered subcutaneously once weekly for 48 weeks.
The results were striking:
- 12mg dose: 24.2% mean body weight reduction at 48 weeks
- 8mg dose: 22.8% mean body weight reduction
- 4mg dose: 17.1% mean body weight reduction
- Placebo: 2.1% mean body weight reduction
For context, these numbers exceed the results seen in pivotal trials of currently approved therapies. Semaglutide 2.4mg (Wegovy) showed approximately 14.9% weight loss at 68 weeks in the STEP 1 trial, while tirzepatide 15mg (Zepbound) demonstrated 22.5% at 72 weeks in SURMOUNT-1. Retatrutide achieved its 24.2% figure in a shorter 48-week timeframe, and the weight loss curves had not yet plateaued — suggesting further reduction with continued treatment.
A sub-study using MRI imaging found that participants on the 12mg dose experienced a roughly 80% reduction in liver fat, which has major implications for non-alcoholic fatty liver disease (NAFLD/MASH). This hepatic fat reduction likely reflects the glucagon component's direct action on liver metabolism.
The Low-Dose Option
An interesting finding from the trial data involves the lower doses. The 1mg and 2mg groups showed meaningful improvements in metabolic markers — including fasting glucose, HbA1c, and lipid panels — with more modest weight loss. This has led some researchers to speculate that low-dose retatrutide could eventually serve as a metabolic health therapy for individuals who do not want or need dramatic weight reduction but would benefit from improved insulin sensitivity, liver fat reduction, and cardiovascular risk factor improvement.
Safety and Side Effects
The most common adverse events in the Phase 2 trial were gastrointestinal, consistent with the GLP-1 drug class:
- Nausea: Reported in up to 25% of participants at higher doses, typically mild-to-moderate and improving after the first few weeks
- Diarrhea: Occurred in approximately 20% at the 12mg dose
- Vomiting: Less common than nausea but present, especially during dose escalation
- Decreased appetite: Frequently reported but generally considered a therapeutic effect rather than a side effect
- Increased heart rate: A modest increase in resting heart rate (2-4 bpm) was observed at higher doses, likely related to the glucagon component's thermogenic action. This warrants monitoring in larger trials.
Dropout rates due to adverse events were relatively low, and no new safety signals emerged compared to existing GLP-1 therapies. However, Phase 2 trials are not powered to detect rare adverse events — that is the purpose of Phase 3.
Current Status and What Comes Next
As of early 2026, retatrutide is in Phase 3 clinical trials. Eli Lilly is running multiple large-scale studies evaluating the drug for obesity, type 2 diabetes, and MASH (metabolic dysfunction-associated steatohepatitis, formerly NAFLD). These trials involve thousands of participants and will provide the robust safety and efficacy data needed for regulatory submission.
If Phase 3 results confirm the Phase 2 findings, retatrutide could receive FDA approval in the 2027-2028 timeframe. However, clinical development timelines are inherently uncertain, and results from larger trials do not always replicate earlier data.
Key Considerations
Several important caveats should inform your understanding of retatrutide:
- Phase 2 limitations: The trial enrolled 338 participants. While results are encouraging, they must be confirmed in larger, longer Phase 3 studies.
- Long-term safety unknown: The glucagon agonist component is novel in this context. Long-term effects of chronic glucagon receptor activation — including potential impacts on liver function, bone density, and cardiovascular health — remain to be characterized.
- Not yet available: Retatrutide is not approved anywhere in the world. Any product sold under this name outside of a clinical trial setting is unregulated and carries unknown risks.
- Weight regain: Like all incretin-based therapies studied to date, weight regain after discontinuation is expected. This likely means long-term or indefinite use for weight maintenance.
The Bottom Line
Retatrutide represents a genuine step forward in the pharmacology of weight management. The addition of glucagon receptor agonism to the GLP-1/GIP backbone creates a mechanistically distinct drug that attacks obesity from both the demand side (reduced appetite) and the supply side (increased energy expenditure). The Phase 2 data showing 24.2% weight loss at 48 weeks — with curves still declining — sets a new benchmark for the field.
That said, this remains an investigational compound. The gap between promising Phase 2 results and a proven, approved therapy is significant, and only Phase 3 data will determine whether retatrutide lives up to its early promise. We will continue to update this page as new data becomes available.
For more on GLP-1 receptor agonists and weight management peptides, explore our peptide database and category guides.